一纸投资公告背后,CXO行业正在经历一场深刻的身份变革。从买地盖楼的重资产模式,到做LP参股创新药企,昭衍新药们的选择折射出整个行业的发展逻辑变迁。(见:昭衍新药越来越爱做LP了……)昭衍新药最近又与倚锋资本联手了。公司公告称,将出资不超过1000万元参与设立深圳市倚锋光明科学城种子基金,瞄准生物医药及高端医疗器械领域。这已是近一年来昭衍新药参与的第三只产业基金。从自建实验室到参股创新药企,CXO...
Source Link一纸投资公告背后,CXO行业正在经历一场深刻的身份变革。从买地盖楼的重资产模式,到做LP参股创新药企,昭衍新药们的选择折射出整个行业的发展逻辑变迁。(见:昭衍新药越来越爱做LP了……)昭衍新药最近又与倚锋资本联手了。公司公告称,将出资不超过1000万元参与设立深圳市倚锋光明科学城种子基金,瞄准生物医药及高端医疗器械领域。这已是近一年来昭衍新药参与的第三只产业基金。从自建实验室到参股创新药企,CXO...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.